London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat cancers

Posted on October 27, 2021 by vulpes-editor

London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat cancers

Contact Us

Tap into Vulpes' wealth of experience and expertise.

Nothing on this website should be construed as an offer to sell or a solicitation of an offer to purchase any investments, securities or products or the giving of any advice in relation to any investments, securities or products in any jurisdiction where such offer or solicitation is not qualified or exempt from registration or permitted by law. The access, use and/or distribution of this website’s information, materials and contents may be restricted by law in certain jurisdictions. It is your sole responsibility to be made aware of and to fully comply with such restrictions.
Vulpes Investment Management Pte. Ltd., and their respective funds, affiliates or subsidiaries does not guarantee the accuracy or completeness of the information, materials and contents on this website and expressly disclaims liability for any errors in, or omissions from, such information, materials and contents or this website in general. Links to other websites from this website are for convenience only. You agree that your access, use and/or distribution of such other websites (including the information, materials and contents therein) is entirely at your own risk and subject to the terms and conditions of access, use and/or distribution contained therein.